Clinical Trial

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.
Protocol Amendment History 2 changes
critical Trial completed 2026-06-23
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-03
Trial Details
NCT Number NCT07431866
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 41 participants
Start Date 2026-03-18
Primary Completion 2026-06-11 (estimated)
Study Completion 2026-06-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-02